Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a license agreement with CSL Behring for the Cytegrity™ stable producer cell line developed and used by St. Jude Children’s Research Hospital (“St. Jude”). Cytegrity™ stable producer cell line will be used to produce the viral vector for Mustang Bio’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (XSCID). Mustang licensed MB-107 from St. Jude in August 2018.
Pfizer Inc. said it plans to spend $500 million to expand a gene-therapy manufacturing facility in Sanford, North Carolina, helping the drug giant scale up production of treatments that fix faulty strands of DNA.
Renovacor, a preclinical-stage gene therapy company, has announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, which were joined by New Leaf Venture Partners and Innogest Capital.
The US company AskBio has acquired the Edinburgh-based Synpromics to pool their gene therapy technologies and produce inducible gene therapies that target particular organs or cells.
Zynteglo is Bluebird's first drug to be approved and is the first gene therapy to be cleared for use in transfusion-dependent beta-thalassemia.
Its marketing authorization from the European Commission follows landmark approvals from the Food and Drug Administration for Novartis' Zolgensma and Spark Therapeutics' Luxturna, which respectively treat spinal muscular atrophy and a type of inherited eye disease.
Private equity firm DCP Capital has reportedly raised some $2.5 billion for its inaugural US dollar- and yuan-denominated funds. That total includes more than $2 billion for DCP Capital Partner I, with the rest going to a yuan vehicle raised at the same time. Among the LPs, per reports: Singaporean investors GIC and Temasek, along with Canadian public pension fund Caisse de depot et placement du Quebec.
InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019. This round of investment was co-led by Advantech Capital and CMBI, followed by Pudong Innotek. Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia.
China’s CDH Investments is aiming to raise nearly $1 billion in dollar and yuan funds through its venture and growth capital arm to invest in sectors including healthcare and logistics, said people with direct knowledge of the matter.
Lilly Asia Ventures has reportedly closed its latest healthcare fund on a $750m hard cap.
Burning Rock Biotech, which was founded in 2014 and focuses on NGS (Next-Generation Sequencing) diagnostics solutions for precision medicine in oncology, today announced the closing of the Series C financing totaling RMB 850 million. The financing was led by GIC, followed by LYFE Capital, CMB International Capital, Lilly Asia Ventures (LAV), Sequoia Capital China and T&Brothers Capital.